/Announcement on Convening the 2026 Semi-annual Performance Briefing
NEWS

Announcement on Convening the 2026 Semi-annual Performance Briefing

Shanghai Stock Exchange
2026/08/08

Securities code: 688505 Securities abbreviation: Fudan Zhangjiang Announcement number: Lin 2026-021

Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.

Announcement on Convening the 2026 Semi-annual Results Briefing Meeting

The board of directors and all directors of the company guarantee that the contents of this announcement do not contain any false records, misleading statements or misleading statements.

serious omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important content reminder:

 Meeting online communication time: August 17, 2026 (Monday) 14:00-15:00 pm

 Meeting place: Shanghai Stock Exchange SSE Roadshow Center (website: http://roadshow.sseinfo.com/)  Meeting method: SSE Roadshow Center online interaction

 Investors can log in to the homepage of the Shanghai Securities Roadshow Center website before 16:00 on August 10, 2026 (Monday) to August 14 (Friday) and click on the "Pre-Solicitation for Questions" column or ask questions through the company's email address [email protected]. The company will answer questions of common concern to investors at the briefing.

Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") will disclose the "2026 Semi-Annual Report of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd." on the website of the Shanghai Stock Exchange (www.sse.com.cn) on August 15, 2026. In order to facilitate investors to have a comprehensive and in-depth understanding of the company's 2026 semi-annual operating results, financial status and development philosophy, the company plans to hold a 2026 semi-annual performance briefing at 14:00-15:00 on August 17, 2026 to communicate on issues of concern to investors.

1. Type of briefing session

This investor briefing will be held in an interactive online format. The company will interact and communicate with investors on the specific operating results and financial indicators for the first half of 2026, and answer questions of common concern to investors to the extent permitted by information disclosure.

2. Time and place of the briefing meeting

(1) Meeting time: August 17, 2026 (Monday) 14:00-15:00 pm

(2) Meeting location: Shanghai Securities Roadshow Center

1/2

(3) Meeting method: Shanghai Securities Roadshow Center online interaction

3. Participants

Chairman, Executive Director, Secretary of the Board of Directors (acting): Mr. Zhao Dajun

Executive Director, General Manager, Financial Director: Ms. Xue Yan

Independent non-executive director: Mr. Wang Hongguang

(If there are special circumstances, participants may make adjustments.)

4. How to participate as an investor

(1) Investors can log in to the SSE Roadshow Center (https://roadshow.sseinfo.com/) via the Internet from 14:00-15:00 on August 17, 2026 (Monday) to participate in this performance briefing online. The company will answer investors’ questions in a timely manner.

(2) Investors can log in to the home page of the SSE Roadshow Center website from August 10, 2026 (Monday) to August 14 (Friday) before 16:00, and click on the "Question Pre-Solicitation" column (https://roadshow.sseinfo.com/question Collection.do), according to the event time, select this event or ask the company via the company email [email protected]. The company will answer questions of common concern to investors at the briefing meeting.

5. Contact person and consultation method

Contact department: Office of the Secretary of the Board of Directors

Contact number: 021-58553583

Email: [email protected]

6. Other matters

After the investor briefing is held, investors can check the status and main content of the investor briefing through the Shanghai Stock Exchange Roadshow Center (http://roadshow.sseinfo.com/).

Announcement is hereby made.

Board of Directors of Shanghai Fudan Zhangjiang Biopharmaceutical Co., Ltd.

August 8, 2026

2/2